Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 591

1.

Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.

Lewis JS, Jordan VC.

Mutat Res. 2005 Dec 11;591(1-2):247-63. Review.

PMID:
16083919
2.

Molecular mechanisms of selective estrogen receptor modulator (SERM) action.

Dutertre M, Smith CL.

J Pharmacol Exp Ther. 2000 Nov;295(2):431-7. Review.

3.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
4.

Therapeutic targeting in the estrogen receptor hormonal pathway.

Katzenellenbogen BS, Frasor J.

Semin Oncol. 2004 Feb;31(1 Suppl 3):28-38. Review.

PMID:
15052541
5.

Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

Park WC, Jordan VC.

Trends Mol Med. 2002 Feb;8(2):82-8. Review.

PMID:
11815274
6.

Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

Jordan VC, O'Malley BW.

J Clin Oncol. 2007 Dec 20;25(36):5815-24. Review.

PMID:
17893378
7.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
8.

Selective estrogen receptor modulators: an update on recent clinical findings.

Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB.

Obstet Gynecol Surv. 2008 Mar;63(3):163-81. doi: 10.1097/OGX.0b013e31816400d7. Review.

PMID:
18279543
9.

Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.

Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W, Berstein L.

Endocr Relat Cancer. 2003 Jun;10(2):111-30. Review.

10.

Estrogen receptors: selective ligands, partners, and distinctive pharmacology.

Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA.

Recent Prog Horm Res. 2000;55:163-93; discussion 194-5. Review.

PMID:
11036937
11.
12.

Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.

Johnston SR.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4376s-4387s; discussion 4411s-4412s. Review.

PMID:
11916228
13.

The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

Lee WL, Cheng MH, Chao HT, Wang PH.

Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Review.

15.

Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

Jordan VC, Gapstur S, Morrow M.

J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review.

16.

Tamoxifen, raloxifene and the prevention of breast cancer.

Bentrem DJ, Craig Jordan V.

Minerva Endocrinol. 2002 Jun;27(2):127-39. Review.

PMID:
11961504
17.

[Selective estrogen receptor modulators (SERMs)].

Matsumoto T.

Clin Calcium. 2006 Sep;16(9):1520-25. Review. Japanese.

PMID:
16951478
18.

Molecular determinants for the tissue specificity of SERMs.

Shang Y, Brown M.

Science. 2002 Mar 29;295(5564):2465-8.

19.
20.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

Oncologist. 2004;9(2):116-25. Review.

Items per page

Supplemental Content

Support Center